Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company that reports a focus on advancing immuno-oncology technologies for difficult to treat cancers. Company news and press releases center on the development of its DNase-based oncology platform, which is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs) involved in cancer progression.
News items for XBIO commonly cover preclinical and translational data from its systemic recombinant human DNase I programs, including the systemic DNase I candidate XBIO-015 in combination with CAR T-cell therapies for hematologic and solid tumors. Updates have described studies conducted with academic collaborators showing that co-administration of DNase I with CAR-T cells can reduce tumor burden, decrease metastatic lesions and extend survival in certain cancer models, while enhancing T-cell infiltration and addressing an immunosuppressive tumor microenvironment.
Another recurring theme in Xenetic’s news flow is collaboration and clinical strategy. The company has announced expanded research and development collaborations with The Scripps Research Institute and a Clinical Trial Services Agreement with PeriNess Ltd. News releases describe exploratory, investigator-initiated clinical studies of systemic DNase I in combination with FOLFIRINOX for unresectable, locally advanced or metastatic pancreatic cancer, and in combination with anti-CD19 CAR T cells in large B cell lymphoma, as well as exploratory plans in osteosarcoma, Ewing sarcoma and colorectal cancer models.
Investors following XBIO news will also find quarterly financial results, details of underwritten offerings conducted under a shelf registration statement, and updates related to annual stockholder meetings and proxy materials. Together, these items provide insight into Xenetic’s progress in advancing its DNase platform toward Phase 1 clinical development, its collaboration-driven development model and its capital-raising activities. Bookmarking this page allows readers to review the sequence of scientific, clinical, financial and corporate announcements directly from the company’s public communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.